Expanded View Figures

Figure EV1. NTRAS is essential for normal endothelial cell function.

- A Illustration of the human NTRAS and GAPDH loci. Displayed are UCSC genome browser snapshots of ribosome profiling GWIPs-viz ribose tracks.
- B Schematic representation of NTRAS transcript variants identified by RT–PCR and 5' RACE–PCR in HUVECs (n = 1).
- C IGV screen shot showing NTRAS expression levels in HUVECs under normoxic (N) and hypoxic (H; 0.2% O₂ for 12 h or 24 h) conditions (n = 2 independent biological replicates).
- D Digital PCR-based analysis of NTRAS copy numbers per µg of total RNA in HUVECs under normoxic (N) and hypoxic (H) conditions (n = 3 independent biological replicates).
- E RT–qPCR-based analysis of VEGFA expression, controlling for hypoxia (n = 4 independent biological replicates).
- F Subcellular localization of NTRAS in normoxic (N) and hypoxic (H) HUVECs, assayed by cellular fractionation and RT-qPCR (n = 3 independent biological replicates).
- G RNAscope-based detection of NTRAS in HUVECs under normoxic and hypoxic conditions (n = 1). Binding sites of the probes are indicated.
- H Validation of NTRAS silencing in HUVECs by RT-qPCR, comparing two different LNAs (n = 4 independent biological replicates).
- Cell cycle analysis in control and NTRAS-silenced HUVECs (n = 3 independent biological replicates).
- J Representative images of *in vitro* sprouting comparing control and NTRAS-silenced HUVECs under basal conditions and VEGFA stimulation (n = 3-10 independent biological replicates). Scale bars are 50 μ m.
- K Illustration of the human and murine NTRAS loci (GRCh38.p13: RP11-354k1.1; GRCm38/mm10: 1700034H15).
- L Validation of Ntras silencing in murine H5V cells by RT-qPCR (n = 3 independent biological replicates).
- M RT-qPCR-based analysis of Ntras expression in hearts of control and Ntras-silenced mice (*n* = 19–23 mice per group).
- N FTSC-based *in vivo* permeability assays, comparing heart homogenates from control and Ntras-silenced mice. Data normalized to organ and body weight (*n* = 11–12 mice per group). Experimental outline on the left.

Data information: In (D–F, H, I, L–N), data are represented as mean \pm SEM. n.s.: non-significant, *P < 0.05, **P < 0.01, ***P < 0.001. (D–F, H, I, L–N) two-tailed unpaired *t*-test.

Source data are available online for this figure.



Figure EV2. NTRAS operates as splicing-regulatory lncRNA.

- A Relative expression of NTRAS in HUVECs and HeLa cells, determined by RT-qPCR (n = 4 independent biological replicates).
- B RT–qPCR-based identification of accessible regions within NTRAS using RNase H-mediated cleavage of RNA–DNA heteroduplexes (DNA antisense oligonucleotides AS1 to AS5) in HUVEC cell lysate (*n* = 1). The oligonucleotide used for probe design is highlighted in red.
- C Scheme illustrating the affinity selection of endogenous NTRAS-protein complexes for RNA and protein analysis.
- D Sucrose density gradient ultracentrifugation showing the distribution of NTRAS and hnRNPL (protein). The dashed box indicates the fractions with the greatest overlap of both factors (*n* = 1).
- E Illustration of the human NTRAS locus. Displayed is NTRAS (GRCh38.p13; RP11-354k1.1) and RBPmap-predicted hnRNPL binding motifs, described elsewhere (Smith *et al*, 2013).
- F Western blot-based validation of NTRAS-hnRNPL interaction following antisense affinity selection of NTRAS in nuclear extracts from normoxic and hypoxic HUVECs (n = 4 independent biological replicates).
- G Expression of NTRAS in control and NTRAS-silenced HUVECs used for RNA sequencing (n = 4 independent biological replicates).
- H hnRNPL mRNA levels in control and hnRNPL-silenced HUVECs used for RNA sequencing (n = 3 independent biological replicates).
- I RT–PCR-based analysis of CD55 intron 7 retention following hnRNPL/NTRAS double knockdown in HUVECs (*n* = 4 independent biological replicates). Representative agarose gel on the right.
- J rMATs-based analysis of alternative splicing events upon silencing of lncRNA lncflow2 in HUVECs (*n* = 4 independent biological replicates) ES: Exon skipping, MXE: Mutually exclusive exons, ASSS: Alternative 5' splice site, A3SS: Alternative 3' splice site, RI: Retained intron.
- K Validation of hnRNPU silencing in HUVECs by RT-qPCR (n = 4 independent biological replicates).
- L RT–PCR-based analysis of TJP1 exon 20 inclusion in hnRNPU-silenced HUVECs (*n* = 4 independent biological replicates).

Data information: In (A, F–I, K, L), data are represented as mean \pm SEM. n.s.: non-significant, **P < 0.01, ***P < 0.001. (A, F–H, K, and L) two-tailed unpaired *t*-test, and (I) one-way ANOVA.

Source data are available online for this figure.



Figure EV2.

Figure EV3. NTRAS controls TJP1 splicing and endothelial barrier function.

- A RT-qPCR-based analysis of TJP1 mRNA expression in hnRNPL-silenced HUVECs (n = 7 independent biological replicates).
- B Relative expression of BCL2, CASP3, CASP6, and CASP9 mRNA in hnRNPL-silenced HUVECs (n = 2 independent biological replicates).
- C RT-qPCR-based analysis of TJP1 mRNA expression in NTRAS-silenced HUVECs (n = 4 independent biological replicates).
- D RT-PCR-based analysis of Tjp1 exon 20 inclusion in control and Ntras-silenced murine CMT93 epithelial cells (n = 3 independent biological replicates).
- E RT-qPCR-based validation of RNase H-mediated NTRAS degradation in HeLa nuclear extracts used for in vitro splicing (n = 4 independent biological replicates).
- F RT–qPCR-based validation of NTRAS overexpression (n = 4 independent biological replicates).
- G Co-precipitation of NTRAS in anti-hnRNPL RIPs, using nuclear lysates from control and NTRAS-overexpressing cells (n = 4 independent biological replicates).
- H RT-PCR-based validation of NTRAS-CA₁₆ motif overexpression (n = 6 independent biological replicates). Representative agarose gel on the right.
- I Quantification of nuclear TJP1, comparing control and NTRAS-silenced HUVECs (*n* = 4 independent biological replicates). Representative micrographs are shown. Scale bars are 10 μm.
- J Analysis of hnRNPL knockdown by western blot 72 h post-transfection of control or hnRNPL-targeting siRNAs (*n* = 4 independent biological replicates). Representative western blots on the right.
- K In vitro permeability assays using FITC-dextran, comparing control and hnRNPL-silenced HUVECs (n = 6 independent biological replicates).
- L In vitro permeability assays using FITC-dextran, comparing control and hnRNPU-silenced HUVECs (n = 4 independent biological replicates).
- M In vitro permeability assays using FITC-dextran, comparing control SSO- and E20 SSO-transfected HUVECs (n = 5 independent biological replicates).

Data information: In (A, C–M) data are represented as mean \pm SEM. n.s.: non-significant, *P < 0.05, **P < 0.01. (A–I) two-tailed unpaired t-test. Source data are available online for this figure.



Figure EV3.





Figure EV4. Characterization of the Ntras CA-repeat in vivo.

- A Illustration of the murine Ntras locus. Displayed is Ntras (GRCm38/mm10; 1700034H15) and RBPmap-predicted hnRNPL binding motifs, described elsewhere (Smith et al, 2013).
- B Genotyping results confirming the genomic deletion of the hnRNPL binding motif in $Ntras^{\Delta CA/\Delta CA}$ mice.
- C RT-qPCR-based analysis of Ntras expression in $Ntras^{CA/CA}$ and $Ntras^{\Delta CA/\Delta CA}$ mice (n = 5-11 mice per group).
- D Western blot-based analysis of the NTRAS-hnRNPL interaction following antisense affinity selection of NTRAS in nuclear fractions from $NTRAS^{CA}$ controls and $NTRAS^{ACA}$ HeLa cells (n = 3 independent biological replicates). Representative western blot on the right.

Data information: In (C, D), data are represented as mean \pm SEM. n.s.: non-significant, *P < 0.05. (C, D) two-tailed unpaired *t*-test. Source data are available online for this figure.